Serina Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Serina Therapeutics, Inc. (NYSE American: SER) is a clinical-stage biotechnology company focused on developing a pipeline of proprietary drug product candidates to treat neurological diseases and other indications. The company's core technology is its proprietary POZ Platform™, which utilizes a synthetic, water-soluble, low-viscosity polymer called poly(2-oxazoline). This platform is engineered to provide precise control over drug loading and release rates, optimizing the pharmacokinetic profiles, tolerability, and dosing of well-understood therapeutics. Serina's lead product candidate is SER-252 (POZ-apomorphine), which is being developed under the FDA's 505(b)(2) regulatory pathway for the treatment of advanced Parkinson's disease. Additionally, the company is advancing SER-270 for Tardive dyskinesia and exploring applications of its POZ technology in lipid nanoparticle (LNP) formulations for RNA-based vaccine delivery, including a non-exclusive licensing agreement with Pfizer.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the Phase 1b registrational clinical study of SER-252, a novel polymer-conjugated therapeutic candidate for the treatment of advanced Parkinson's disease.
Expected impact: Provide clinical validation of the proprietary POZ Platform™ drug optimization technology.
Expanding the applications of the proprietary POZ Platform™ drug optimization technology via out-licensing, co-development, or other partnership arrangements across multiple modalities including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs).
Expected impact: Unlock meaningful value across multiple therapeutic modalities and secure non-dilutive funding through milestone and royalty payments.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Serina merged with a wholly-owned subsidiary of AgeX in an all-stock transaction to create a combined clinical-stage biotechnology company focused on developing therapies for Parkinson's Disease and other neurological diseases.
Financial impact: Provided Serina with a public listing platform on the NYSE American market.
Strategic Partnerships
Allows Pfizer to use Serina's proprietary POZ polymer technology for lipid nanoparticle drug (LNP) delivery formulations, validating the platform's utility in advanced drug delivery.
Terms: Includes a one-time upfront payment of $3 million received on December 15, 2023, milestone payments upon the achievement of specific development, regulatory, and commercial milestones, and tiered royalties on net sales between 2.75% and 3.5%.